Biocompatibles announces new deals and funding plans in a busy week
This article was originally published in Clinica
Executive Summary
Last week Biocompatibles announced it had formed an R&D deal with Boston Scientific, established eight distribution agreements for its DivYsio coronary stents and announced plans to secure £29 million ($47 million) in funding for the next year.